1️⃣ ‘Summer of hell’: What’s typically a key money-making time for airlines could fall short this year. Fears about flying, ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

In a retrospective cohort study using propensity matching, among patients with obesity, those taking semaglutide had lower ...

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...